Payment overview · 2025
General Payments
$1,264.16
52 reported records · 19 companies
Healthcare provider profile · identity verified
Fidel Garcia, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, FL · NPI 1790779262
Verified facts
What the public records show
CMS Open Payments records show Fidel Garcia, MD received $1,264.16 in general payments during 2025 across 52 reported records.
SCPHARMACEUTICALS INC. accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Paxlovid, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 87 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $165.63 | 13.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $149.24 | 11.8% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $138.62 | 11.0% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $113.18 | 8.9% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $74.12 | 5.9% | 5 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $64.40 | 5.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $64.29 | 5.1% | 4 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.60 | 4.9% | 3 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $59.14 | 4.7% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $57.66 | 4.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $51.67 | 4.1% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $47.43 | 3.8% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.50 | 3.3% | 2 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $41.45 | 3.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $37.07 | 2.9% | 2 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $33.35 | 2.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $24.79 | 2.0% | 1 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.98 | 1.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.04 | 1.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,264.16 | 52 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $165.63 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $138.62 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $82.98 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $73.76 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $73.76 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $64.40 | 3 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $64.16 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.23 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $59.23 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $59.14 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $57.66 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $50.60 | 3 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $48.84 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $33.47 | 2 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $33.35 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.34 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $22.94 | 1 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $20.53 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $19.98 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.04 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.41 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.42 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $13.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 196 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 83 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 72 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 93 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 87 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 34 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
83 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
72 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
93 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
87 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
196 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
34 | 32 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 741 | 213 |
| Atorvastatin Calcium | Atorvastatin Calcium | 510 | 152 |
| Amlodipine Besylate | Amlodipine Besylate | 479 | 140 |
| Levothyroxine Sodium | Levothyroxine Sodium | 391 | 108 |
| Losartan Potassium | Losartan Potassium | 323 | 89 |
| Metoprolol Succinate | Metoprolol Succinate | 316 | 88 |
| Montelukast Sodium | Montelukast Sodium | 250 | 77 |
| Omeprazole | Omeprazole | 235 | 73 |
| Metformin Hcl | Metformin Hcl | 233 | 63 |
| Lisinopril | Lisinopril | 226 | 72 |
| Valsartan | Valsartan | 219 | 67 |
| Metoprolol Tartrate | Metoprolol Tartrate | 207 | 65 |
| Pantoprazole Sodium | Pantoprazole Sodium | 199 | 60 |
| Eliquis | Apixaban | 196 | 41 |
| Tamsulosin Hcl | Tamsulosin Hcl | 192 | 60 |
| Gabapentin | Gabapentin | 179 | 57 |
| Carvedilol | Carvedilol | 174 | 50 |
| Pravastatin Sodium | Pravastatin Sodium | 173 | 50 |
| Simvastatin | Simvastatin | 156 | 41 |
| Ezetimibe | Ezetimibe | 154 | 49 |
| Alprazolam | Alprazolam | 149 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 145 | 44 |
| Sertraline Hcl | Sertraline Hcl | 141 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 41 |
| Furosemide | Furosemide | 127 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 127 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 119 | 31 |
| Potassium Chloride | Potassium Chloride | 116 | 38 |
| Glimepiride | Glimepiride | 113 | 28 |
| Meloxicam | Meloxicam | 110 | 38 |
| Duloxetine Hcl | Duloxetine Hcl | 101 | 21 |
| Allopurinol | Allopurinol | 99 | 33 |
| Tramadol Hcl | Tramadol Hcl | 98 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 97 | 32 |
| Mounjaro | Tirzepatide | 93 | 20 |
| Ozempic | Semaglutide | 87 | 15 |
| Trazodone Hcl | Trazodone Hcl | 86 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 85 | 38 |
| Ibuprofen | Ibuprofen | 85 | 30 |
| Farxiga | Dapagliflozin Propanediol | 83 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 77 | 19 |
| Synthroid | Levothyroxine Sodium | 74 | 16 |
| Methylprednisolone | Methylprednisolone | 73 | 63 |
| Diclofenac Sodium | Diclofenac Sodium | 72 | 23 |
| Jardiance | Empagliflozin | 72 | 18 |
| Metformin Hcl Er | Metformin Hcl | 72 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 71 | 20 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 68 | 24 |
| Finasteride | Finasteride | 68 | 23 |
| Mirtazapine | Mirtazapine | 68 | 19 |
| Entresto | Sacubitril/Valsartan | 66 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 21 |
| Azithromycin | Azithromycin | 58 | 49 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 57 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 57 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 56 | 15 |
| Repatha Sureclick | Evolocumab | 55 | 12 |
| Pregabalin | Pregabalin | 53 | 18 |
| Buspirone Hcl | Buspirone Hcl | 48 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 19 |
| Famotidine | Famotidine | 47 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 45 | 39 |
| Atenolol | Atenolol | 44 | 12 |
| Spironolactone | Spironolactone | 44 | 16 |
| Alendronate Sodium | Alendronate Sodium | 43 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 13 |
| Lorazepam | Lorazepam | 42 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 42 | 13 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 41 | 30 |
| Verapamil Er | Verapamil Hcl | 41 | 12 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 40 | 12 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 39 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Clonidine Hcl | Clonidine Hcl | 38 | 14 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 37 | 12 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Celecoxib | Celecoxib | 36 | 12 |
| Nifedipine Er | Nifedipine | 36 | 14 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 12 |
| Benazepril Hcl | Benazepril Hcl | 34 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 34 | 32 |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 11 |
| Estradiol | Estradiol | 30 | suppressed |
| Fenofibrate | Fenofibrate | 30 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 30 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 28 | 26 |
| Nystatin | Nystatin | 28 | suppressed |
| Ramipril | Ramipril | 27 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 14 |
| Telmisartan | Telmisartan | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 25 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 25 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 25 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 24 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 24 | 18 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Mupirocin | Mupirocin | 22 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 22 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Digoxin | Digoxin | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Levemir Flexpen | Insulin Detemir | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 20 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bumetanide | Bumetanide | 19 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Prednisone | Prednisone | 19 | 14 |
| Premarin | Estrogens, Conjugated | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 18 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | 13 |
| Sucralfate | Sucralfate | 16 | suppressed |
| Tradjenta | Linagliptin | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Belsomra | Suvorexant | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Edarbi | Azilsartan Medoxomil | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Cephalexin | Cephalexin | 13 | 12 |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Januvia | Sitagliptin Phosphate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Temazepam | Temazepam | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Jantoven | Warfarin Sodium | 12 | suppressed |
| Lansoprazole | Lansoprazole | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Tirosint | Levothyroxine Sodium | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zaleplon | Zaleplon | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,264.16 · 52 records | SCPHARMACEUTICALS INC. | ABRYSVO, AIRSUPRA, APLENZIN, AREXVY, BREZTRI, CAPLYTA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, FUROSCIX, GARDASIL 9, Heplisav-B, JARDIANCE, Kerendia, Korlym, Leqembi, MOUNJARO, NURTEC ODT, OFEV, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, PROLIA, REPATHA, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, Veozah, Wegovy | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error